HUINNO Co., LtdS2.C52HUINNO is a healthcare startup developing wearable solutions, most notably patch, mounted with cardiac monitoring technology with cutting-edge AI-based cloud analysis software. They enable easy and convenient diagnosis and treatment of patients with cardiac diseases such as arrhythmia and atrial fibrillation, which are hard to diagnose with conventional medical devices. They also facilitate fast diagnosis and treatment of cardiac diseases at affordable costs and provide services beneficial for all stakeholders including hospitals/clinics, physicians, and patients. So far, HUINNO’s products include MEMO Care, MEMO Cue and MEMO AI. HUINNO has started providing its services after establishing partnerships with Seoul National University Hospital, Korea University Hospital, and Yuhan Corp.
Huinno has two types of technologies. First is MEMO AI, an AI-based biosignal analysis solution. The solution analyzes various biosignals such as ECG, oxygen saturation, and heart rate, and provides information useful for the diagnosis of arrhythmia and hypertension. MEMO AI includes a model learned using data from up to 400,000 patients, demonstrating ECG reading precision of 97%. This figure by far surpasses the performance of conventional algorithms (~70%). MEMO AI can help medical institutions increase diagnosis precision and save a significant amount of time spent on ECG data screening and diagnosis, thereby enhancing efficiency of medical services.
The second type of HUINNO’s technology enables convenient measurement and monitoring of various biosignals for an extended period of time. The company develops and produces devices of various forms, allowing the users to choose what suits them the most. Moreover, HUINNO’s devices, equipped with ultra-low power technology, can be used without recharging for an extended period of time.
